ScreenIn3D

ScreenIn3D is a start-up company co-founded by Michele Zagnoni and Alex Sim in 2018. The company is based in the Technology and Innovation Centre at the University of Strathclyde. ScreenIn3D utilises the latest advances in microfluidics and 3D culture to develop a unique microfluidic screening platform.

Using our propriety ONCO-Chip3D technology – ScreenIn3D offers high quality pre-clinical screening services to biotech and pharmaceutical companies with interest in developing new oncology assays. This helps provide our customers with the confidence to take a leap forward to advanced stages of drug approval.

The unique combination of microfluidic lab-on-a-chip technology with physiologically relevant 3D cancer models is designed to make drug discovery more closely relevant with what happens in the body. The ability to micro size drug-cell interactions will allow pharmaceutical and biotech companies do 100x more testing for the same money spent as well as increasing productivity as it enables more experiments to be done on the same platform at the same time.

Combines microfluidic lab-on-a-chip technology with physiologically relevant multicellular spheroids to enable formation and long-term culture of 3D tumor models for drug screening and individualized chemosensitivity testing.

Targeted drug discovery and development
Allows companies to do 1000x more testing for the same spend
Facilitating combination therapy for better disease management
Provides a robust, time-effective platform for personalised medicine

2018